Evidence map›Paper›PMID 30030493›Full record

ArticleCellular & molecular immunology2019

In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity.

Merylin Cottagiri, Maeva Nyandjo, Matthew Stephens, Joel J Mantilla, Hirohisa Saito, Ian R Mackay, Noel R Rose, Dolores B Njoku

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. IL-33 Signaling Inhibition Leads to a Preeclampsia-Like Phenotype in Pregnant Rats.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024
    Article
  3. Article
  4. Review
  5. Liver-Mediated Adaptive Immune Tolerance.Frontiers in immunology · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Merylin CottagiriDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 1800 Orleans Street, Suite 6349, Baltimore, MD, 21287, USA.
Maeva NyandjoDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 1800 Orleans Street, Suite 6349, Baltimore, MD, 21287, USA.
Matthew StephensDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 1800 Orleans Street, Suite 6349, Baltimore, MD, 21287, USA.
Joel J MantillaDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 1800 Orleans Street, Suite 6349, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0002-4624-7231
Hirohisa SaitoRIKEN Center for Developmental Biology, 2-2-3 Minatojima Minamimachi, Chuo-ku, Kobe, Japan, 650-0047.
Ian R MackayDepartment of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Melbourne, Australia.
Noel R RoseDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.
Dolores B NjokuDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 1800 Orleans Street, Suite 6349, Baltimore, MD, 21287, USA. dnjoku@jhmi.edu.ORCID http://orcid.org/0000-0002-5458-4596
Johns Hopkins University · USBrigham and Women's Hospital · USMonash University · AURIKEN Center for Computational Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune-mediated, drug-induced hepatitis is a rare complication of halogenated volatile anesthetic administration. IL-4-regulated Th2-polarized reactions initiate this type and other types of hepatitis, while the mechanisms that regulate the severity remain elusive. IL-33 is an innate, IL-4-inducing, Th2-polarizing cytokine that has been detected in patients with liver failure and has been associated with upregulated ST2+Foxp3+CD4+CD25+ T cells; however, roles for IL-33 in drug-induced hepatitis are unclear. We investigated IL-33 in an anesthetic, immune-mediated hepatitis modeled in BALB/c, IL-33-/- and ST2-/- mice, as well as in patients with anesthetic hepatitis. The hepatic IL-33 and ST2 levels were elevated in BALB/c mice (p < 0.05) with hepatitis, and anti-IL-33 diminished hepatitis (p < 0.05) without reducing IL-33 levels. The complete absence of IL-33 reduced IL-10 (p < 0.05) and ST2+Foxp3+CD4+CD25+ T cells (p < 0.05), as well as reduced the overall survival (p < 0.05), suggesting suppressive roles for IL-33 in anesthetic, immune-mediated hepatitis. All of the mice demonstrated similar levels of CD4+ T-cell proliferation following direct T-cell receptor stimulation, but we detected splenic IL-33 and ST2-negative Foxp3+CD4+CD25+ T cells in ST2-/- mice that developed less hepatitis than BALB/c mice (p < 0.05), suggesting that ST2-negative Foxp3+CD4+CD25+ T cells reduced hepatitis. In patients, serum IL-33 and IPEX levels were correlated in controls (r

Indexed as

AnimalsCD4-Positive T-LymphocytesCell ProliferationChemical and Drug Induced Liver InjuryCytochrome P-450 CYP2E1Disease Models, AnimalEpitopesFemaleFluoroacetatesForkhead Transcription FactorsHumansInterleukin-1 Receptor-Like 1 ProteinInterleukin-2 Receptor alpha SubunitInterleukin-33MiceMice, Inbred BALB Ccytochrome P-450 2E1, mouseCytochrome P-450 CYP2E1EpitopesFluoroacetatesForkhead Transcription FactorsFOXP3 protein, humanFoxp3 protein, mouseIl1rl1 protein, mouseIL2RA protein, humanIL33 protein, humanIl33 protein, mouseInterleukin-1 Receptor-Like 1 ProteinInterleukin-2 Receptor alpha SubunitInterleukin-33trifluoroacetyl chlorideautoimmunitydrug-inducedFoxp3+ TregshepatitisIL-33immune-mediated

Identifiers

PMID30030493
PMCPMC6804902
OpenAlexW2883143502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.